Peptide library › Metabolic & weight
Amycretin
Experimental single molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and a daily tablet for weight loss.
What people use it for
- Obesity and overweight (in trials)
What Amycretin does in the body
One molecule that activates two appetite systems: GLP-1 receptors, like semaglutide, and amylin receptors, like cagrilintide. Both reduce hunger and slow stomach emptying, and combining them may give more weight loss than either alone.
Strength of evidence
Moderate: early-phase (Phase 1/2) trials showed large weight loss in people with overweight or obesity. Large Phase 3 trials are still needed.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Nausea, vomiting and diarrhoea, mostly while the dose is increased
- Reduced appetite
- Long-term safety unknown
Who should avoid it or take extra care
- Anyone outside a clinical trial, as it isn't available as a medicine
- Pregnancy or breastfeeding, unless a specialist advises it
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
Investigational. Not approved by the FDA or any regulator.
How it's taken
Route: Injection under the skin once weekly, or a daily tablet (in trials)
How long it lasts (half-life): Long-acting injection designed for weekly dosing; full data not yet published
Keep track of Amycretin privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Amycretin in Fiala How to installMore in Metabolic & weight
- SemaglutideOnce-weekly GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
- TirzepatideOnce-weekly dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management.
- RetatrutideExperimental triple GIP / GLP-1 / glucagon receptor agonist being studied for obesity.
- AOD-9604Modified fragment of human growth hormone once developed as an anti-obesity drug.
- LiraglutideOnce-daily GLP-1 receptor agonist; the predecessor of semaglutide.
- CagrilintideLong-acting amylin analog being studied for weight loss, mainly combined with semaglutide.
- MazdutideOnce-weekly dual GLP-1 and glucagon receptor agonist for weight management.
- SurvodutideExperimental once-weekly dual glucagon and GLP-1 receptor agonist being studied for obesity and fatty liver disease.
- DulaglutideOnce-weekly GLP-1 receptor agonist approved for type 2 diabetes.
- ExenatideThe first GLP-1 receptor agonist, originally found in Gila monster venom, approved for type 2 diabetes.
- PramlintideSynthetic version of the hormone amylin, used with mealtime insulin in diabetes.
- SetmelanotideMC4R agonist approved for rare genetic causes of severe obesity.
- 5-Amino-1MQSmall molecule sold alongside peptides for fat loss; blocks the enzyme NNMT. Not a peptide, and untested in people.
- AlbiglutideOnce-weekly GLP-1 medicine for type 2 diabetes, discontinued for business reasons in 2018.
- EfpeglenatideLong-acting experimental GLP-1 medicine that cut heart and kidney events in people with type 2 diabetes in a large trial.
- LixisenatideOnce-daily GLP-1 medicine for type 2 diabetes, now mainly used in a combined pen with insulin glargine.
- PemvidutideExperimental weekly injection that acts on GLP-1 and glucagon receptors, studied for obesity and fatty liver disease.
- PetrelintideExperimental long-acting amylin analog given weekly for weight loss, aiming for fewer stomach side effects than GLP-1 drugs.
- Insulin analogsLab-modified versions of insulin that work faster or last longer, used to treat type 1 and type 2 diabetes.
- GlucagonEmergency hormone that quickly raises blood sugar during a severe hypo; also used to relax the gut during scans.
- DasiglucagonStable, ready-to-use version of glucagon for treating severe low blood sugar in people with diabetes.